Intellia Therapeutics, Inc.NTLA
ASignal's systematic analysis rates NTLA as Bearish.
Reflects the latest available analysis · analyzed Aug 14, 2026
The case on NTLA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $437.76M in total cash
- Low debt-to-equity ratio of 0.10x indicating conservative capital structure
- Current ratio of 6.65x suggests strong short-term liquidity
- MACD histogram showing narrowing bearish momentum
- Severely negative operating margin (-1472.26%)
- Negative return on equity (-55.44%) and return on assets (-30.14%)
- Revenue growth declining YoY by 46.20%
- Negative free cash flow at $-249.83M
- Forward P/E of -4.57x indicates unprofitability
- EV/EBITDA of -3.12x signals weak earnings base
See the full verdict on NTLA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NTLA
Most investors never get a second opinion, let alone several. ASignal runs NTLA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.